Lannett (LCI) Reports Prelim. Q4 Results, Provides Update On Contract Renewal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Lannett Provides Update On Contract Renewal With Jerome Stevens Pharmaceuticals
August 20, 2018 6:53 AM EDTPHILADELPHIA, Aug. 20, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today said that its distribution agreement with Jerome Stevens Pharmaceuticals (JSP), which expires on March 23, 2019, will not be renewed.
"The Steinlauf family advised us this past Friday evening that they will not renew our agreement to distribute three JSP products: Butalbital,... More



